Int Arch Otorhinolaryngol 2016; 20(04): 382-389
DOI: 10.1055/s-0036-1583168
Systematic Review
Thieme Publicações Ltda Rio de Janeiro, Brazil

Clinical Value of High Mobility Group Box 1 and the Receptor for Advanced Glycation End-products in Head and Neck Cancer: A Systematic Review

Austin Nguyen
1  Department of Clinical and Translational Science, Creighton University School of Medicine, Omaha, Nebraska, United States
,
Sheila Bhavsar
1  Department of Clinical and Translational Science, Creighton University School of Medicine, Omaha, Nebraska, United States
,
Erinn Riley
1  Department of Clinical and Translational Science, Creighton University School of Medicine, Omaha, Nebraska, United States
,
Gabriel Caponetti
2  Department of Pathology, Creighton University School of Medicine, Omaha, Nebraska, United States
,
Devendra Agrawal
1  Department of Clinical and Translational Science, Creighton University School of Medicine, Omaha, Nebraska, United States
› Author Affiliations
Further Information

Publication History

20 January 2016

28 February 2016

Publication Date:
19 April 2016 (eFirst)

  

Abstract

Introduction High mobility group box 1 is a versatile protein involved in gene transcription, extracellular signaling, and response to inflammation. Extracellularly, high mobility group box 1 binds to several receptors, notably the receptor for advanced glycation end-products. Expression of high mobility group box 1 and the receptor for advanced glycation end-products has been described in many cancers.

Objectives To systematically review the available literature using PubMed and Web of Science to evaluate the clinical value of high mobility group box 1 and the receptor for advanced glycation end-products in head and neck squamous cell carcinomas.

Data synthesis A total of eleven studies were included in this review. High mobility group box 1 overexpression is associated with poor prognosis and many clinical and pathological characteristics of head and neck squamous cell carcinomas patients. Additionally, the receptor for advanced glycation end-products demonstrates potential value as a clinical indicator of tumor angiogenesis and advanced staging. In diagnosis, high mobility group box 1 demonstrates low sensitivity.

Conclusion High mobility group box 1 and the receptor for advanced glycation end-products are associated with clinical and pathological characteristics of head and neck squamous cell carcinomas. Further investigation of the prognostic and diagnostic value of these molecules is warranted.